CYTODYN INC. DL -,01 WKN: A0YHA5 ISIN: US23283M1018 Kürzel: 296 Forum: Aktien Thema: Hauptdiskussion

Es ist eher eine frage der persönlichen Überzeugung....viele schieben Panik... Richtig schlecht wäre es wenn es hier nur um corona ginge.

Ich halte das wie gesagt noch mindestens 6 Monate...Leronlimab bleibt top für mich... Und ist nicht nur auf Corona bezogen.... Es wird auch mehr als nur ein Impfstoff geben.

Ja hab ich gelesen , nur was wird jetzt aus Cytodyn ? Verkaufen oder halten 🤔

Zumindest die small und mid caps

Fast alle BIOS sind unten

Biontech hat die Zulassung beantragt und ihr Impfstoff hat 90% Wirksamkeit

Schei.ße was ist heute los

🙏

Na das hört sich doch mal gut an . Super Arbeit Jamil 👍

Menu Yahoo Mail Search  Jetzt vorbestellen & vorab downloaden AnzeigePlayStation Summary Company Outlook Conversations Statistics Historical Data Profile Financials Analysis Options Holders Sustainability CYDY - CytoDyn Inc. Other OTC - Other OTC Delayed Price. Currency in USD 80,340 reactions on $CYDY conversation Sign in to post a message. 8 viewing Top Reactions  dave6 hours ago Crain’s Health Pulse article today. This is a subscription based publication read by NY’s health care leaders. Montefiore to lead trial of patients with long-term Covid symptoms Montefiore Medical Center will be participating in and leading a clinical trial exploring the use of a drug that regulates the immune system for patients suffering lingering symptoms following a Covid-19 infection. The Bronx-based hospital will be recruiting up to 60 of the 100 patients in a phase three study of leronlimab, a monoclonal antibody drug that blocks precursors of inflammation, said Dr. Harish Seethamraju, medical director of the advanced lung failure and lung transplant program.

Sorry irgendwie kopiert der nicht den ganzen Text....

the advanced lung failure and lung transplant program. The trial should start in about three weeks, said Nader Pourhassan, president and CEO of CytoDyn, the Vancouver, Wash.–based pharmaceutical company developing the drug. The protocol of the eight-week trial, which costs about $5 million, will be submitted to the U.S. Food and Drug Administration next week, Pourhassan said. The study will examine how the drug improves fatigue among other lingering symptoms, he added. Montefiore will be the only New York hospital involved in this study as well as an ongoing phase three trial of leronlimab in severe-to-critical Covid-19 patients, Seethamraju said. The hospital, which recruited 19 patients for the current trial, had also led a phase two trial on mild-to-moderate Covid-19 disease, he added. The trial for severe-to-critical Covid-19 patients, which costs about $9 million, has recruited 247 of its targeted 390 patients, Pourhassan said. The FDA has agreed to review its efficacy results at the 75% recruitment point, which could be hit as soon as next week, Seethamraju said. "This could potentially grant it emergency-use authorization for a segment of Covid-19 patients who don't have any available options," Seethamraju said. Leronlimab is CytoDyn's lead drug candidate and has not yet been approved for any disease. It was originally developed for HIV, cancer and autoimmune disease treatment, but Seethamraju had recommended its development for Covid-19 upon observing benefits with its method of action. CytoDyn, founded in 2000, reported a net loss of $124 million and assets of $50.5 million in the fiscal year that ended May 31.

OK hier nochmal ganz

submitted to the U.S. Food and Drug Administration next week, Pourhassan said. The study will examine how the drug improves fatigue among other lingering symptoms, he added. Montefiore will be the only New York hospital involved in this study as well as an ongoing phase three trial of leronlimab in severe-to-critical Covid-19 patients, Seethamraju said. The hospital, which recruited 19 patients for the current trial, had also led a phase two trial on mild-to-moderate Covid-19 disease, he added. The trial for severe-to-critical Covid-19 patients, which costs about $9 million, has recruited 247 of its targeted 390 patients, Pourhassan said. The FDA has agreed to review its efficacy results at the 75% recruitment point, which could be hit as soon as next week, Seethamraju said. "This could potentially grant it emergency-use authorization for a segment of Covid-19 patients who don't have any available options," Seethamraju said. Leronlimab is CytoDyn's lead drug candidate and has not yet been approved for any disease. It was originally developed for HIV, cancer and autoimmune disease treatment, but Seethamraju had recommended its development for Covid-19 upon observing benefits with its method of action. CytoDyn, founded in 2000, reported a net loss of $124 million and assets of $50.5 million in the fiscal year that ended May 31.

Gerade gefunden aus dem yah forum

Copied from other board- So biggest things revealed on Today’s conference call are as follows #1 statisticians have provided CD-12 data to FDA. #2 OWS has been in discussions with CYDY and that EAU is on the table especially since FDA now has our data. Expectation is if we get EUA for CD-12 we should get OWS funding help and manufacturing. #3 We also have a unnamed billionaire that if data shows reduces mortality he will personally step in and help with funding. #4 Heavily focused on getting to 293 enrollment currently near 250, significant person Brian B. going around to many of the hospital sites to get us listed as priority. #5 BLA is being worked on for U.K submission still seen as quickest path for approval #6 Long Haulers FDA trial protocol being fine tuned to best position CYDY for future vital indications hopefully submit in a week or so. #7 Canada meeting for HIV next week! #8 Nash hope to enroll patients this year #9 what lawsuits? Oh Bogus investigations what they are